Book demo
Log in
Companies
Vaishali Pharma
Q4 25/26
Logotype for Vaishali Pharma Limited

Vaishali Pharma (VAISHALI) Q4 25/26 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Vaishali Pharma Limited

Q4 25/26 earnings summary

30 May, 2026

Executive summary

  • Audited standalone and consolidated financial results for the quarter and year ended 31 March 2026 were approved, with the first-time consolidation of Kesar Pharma Limited as an associate from September 2025.

  • Audit reports for both standalone and consolidated results were issued with unmodified opinions, except for uncertainty regarding long-outstanding receivables.

Financial highlights

  • Standalone revenue from operations for FY26 was ₹10,877.23 lakh, up from ₹9,902.56 lakh in FY25.

  • Standalone net profit for FY26 was ₹403.17 lakh, compared to ₹81.74 lakh in FY25.

  • Consolidated revenue for FY26 was ₹10,877.23 lakh, with consolidated net profit at ₹403.17 lakh and share of profit from associate at ₹13.31 lakh.

  • Earnings per share (EPS) for FY26 stood at ₹0.31 (standalone) and ₹0.32 (consolidated).

Outlook and guidance

  • No explicit forward-looking guidance provided; management notes the first-time consolidation of an associate and ongoing focus on pharmaceutical sales.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Vaishali Pharma

View more events